Session Type: Abstract Submissions (ACR)
Background/Purpose: To evaluate the association between anti-cyclic citrullinated peptide antibody titres (anti-CCP) and other clinical factors with the presence and severity of Interstitial Lung Disease in patients with Rheumatoid Arthritis (ILD-RA).
Methods: A total of 81 RA patients were included in a cross-sectional study. Forty-one patients with ILD-RA were compared with 40 Rheumatoid Arthritis without pulmonary involvement (RA w/out). ILD was screened with pulmonary function tests (PFT) and diagnosed by definite findings in the high-resolution computed tomography (HRCT). Clinical impact of ILD was evaluated with PFP, six-minute walk test (6MWT); Borg scale, Saint George’s respiratory scale (SGRQ), and severity of ILD according to the HRCT score. Serum anti-CCP levels were measured by ELISA. Multivariate logistic regression was conducted to identify independent risk factors for ILD-RA.
Results: There was no difference in the frequency of smoking history between the group ILD-RA compared with the group of RA w/out (23.1% vs. 31.0% respectively, p = 0.46). The group of ILD-RA has higher score of DAS28 compared with RA w/out (3.59 ± 1.09 vs. 2.77 ± 0.84 respectively, p <0.001), HAQ-Di, (0.90 ± 0.52 vs. 0.58 ± 0.45 respectively, p < 0.05) and higher frequency of positive anti-CCP (100% vs. 64.3%, p < 0.001). Anti-CCP titres correlated with severity of dyspnea (r=0.535, p <0.001), SGRQ symptoms (r = 0.547, p <0.001), SGRQ activity (r = 0.616, p <0.001), SGRQ impact (r = 0.523, p <0.001), HCRT alveolar score (r = 0.695, p <0.001), HCRT interstitial score (r = 0.547, p <0.001) and HCRT total score (r = 0.549, p <0.001). In the multivariate analysis, after adjusting by age, disease duration, smoking status and disease activity anti-CCP titres remained as a risk factor (OR, 1.06; 95%CI, 1.02-1.10; p= 0.001) as well as duration of treatment with methotrexate (OR, 2.82; 95%CI, 1.51-5.29 p = 0.001).
High anti-CCP titers are associated with the severity of the ILD secondary to RA. Follow-up studies are required to identify if patients with higher titers of this antibody are associated with a poor outcome in patients suffering ILD-RA.
J. M. Ponce-Guarneros,
A. D. Rocha Muñoz,
J. I. Gámez Nava,
S. A. Zavaleta Muñíz,
M. L. Díaz Toscano,
M. Salazar Paramo,
L. F. De La Cerda Trujillo,
N. G. González Montoya,
E. G. Cardona Muñoz,
M. Vazquez del Mercado,
L. González López,
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-anti-cyclic-citrullinated-peptide-antibodies-titres-and-the-presence-and-severity-of-diffuse-interstitial-lung-disease-secondary-to-rheumatoid-arthritis/